First-Line Encorafenib, Cetuximab, and FOLFIRI in BRAF-Mutant Colorectal Cancer

A Flexible Chemotherapy Backbone: The approval allows the targeted combination (Encorafenib + Cetuximab) to be combined with either mFOLFOX6 or FOLFIRI regimens, giving clinicians the opportunity to make patient-specific choices.

Approved Regimen

Encorafenib + Cetuximab + Chemotherapy

---

• Targeted Therapy: Encorafenib + Cetuximab
• Chemotherapy Option 1: mFOLFOX6 (Oxaliplatin)
• Chemotherapy Option 2: FOLFIRI (Irinotecan)

Control Arm

Standard of Care

---

• Standard Chemotherapy: FOLFOX / FOLFIRI / CAPOX
• Optional: Addition of bevacizumab

Median Overall Survival (OS)

30.3 Months

Median Overall Survival (OS)

15.1 Months

DROZDOGAN Academic Note:

BRAF V600E-mutant metastatic colorectal cancer has been one of the most challenging areas in oncology, but combining encorafenib + cetuximab with chemotherapy has completely changed this picture. The overall survival of 30.3 months supporting traditional approval can be considered a “milestone” for this patient group.

Clinical Practice and Freedom of Choice:
The FDA approval covers both mFOLFOX6 and FOLFIRI backbones, allowing us to offer a personalized treatment plan according to a patient's toxicity profile (for example, choosing FOLFIRI for patients with pre-existing neuropathy). This regimen is now the undisputed new standard for first-line treatment of BRAF-mutant mCRC.

In conclusion, this triplet combination should be considered the first option for every patient with a detected BRAF V600E mutation to maximize disease control and prolong survival.